FDA Calendar for InterMune, Inc. (ITMN)

| Register (free)
InterMune, Inc. (InterMune) is a biotech company focused on developing and commercializing therapies in pulmonology and hepatology. As of December 31, 2008, the Company’s development programs included pirfenidone for idiopathic pulmonary fibrosis (IPF) and the hepatitis C virus (HCV) protease inhibitor program. In October 2006, the Company entered into an agreement with Hoffmann-LaRoche Inc. and F. Hoffmann-LaRoche Ltd. (Roche) to develop and commercialize products from its chronic HCV protease inhibitor program, including its lead candidate compound ITMN-191. Effective March 2007, the Company discontinued development of Actimmune for IPF.


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
Pirfenidone/Esbriet Other Pending DecisionNDA


Events

No future events listed at this time, please check back later.
2 past event(s) found. Click here to view them.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

ITMN

$16.00
-0.01 -0.06%
2/3/2012 4:00:00 PM

Trade Idea!

05/07/2010

Currently ITMN is trading at 11.10. The way the market has been this past week. I would stay away from this stock. It is very volatile and there weren't any press releases from the company to try and reassure its investors.

Sponsors

Other Links